Trial Profile
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Mar 2007 New trial record.